Rgenta Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Trial Design for RGT-61159 in Patients with Adenoid Cystic Carcinoma (ACC)
AltruBio Presents Phase 2a Data of ALTB-268 in Advanced Therapy-Refractory Ulcerative Colitis at UEG Week 2026
Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig
Rgenta Therapeutics Announces RGT-61159 Poster Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure
Rejoni Receives FDA Approval of the Juveena® Hydrogel System to Reduce Intrauterine Adhesions Following Hysteroscopic Adhesiolysis
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
Phanes Therapeutics announces US patent granted to its proprietary bispecific antibody technology platform PACbody®
